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BACKGROUND: Coronary artery disease (CAD) is a multifactorial condition, involving also genetic factors. Among candidate genes associated 
with CAD risk there are lipoprotein lipase (LPL) gene and APOC3 gene. APOC3 encodes for the apolipoprotein CIII (ApoCIII) which acts as an 
inhibitor of LPL. Three different ApoCIII glycoforms (with different LPL inhibitory activity) - characterized by none, one or two sialic acids - have 
been described. Changes in the relative abundance of these glycoforms have been observed in a variety of pathologies. 
The aim of this study was to analyze and quantify the apoCIII glycoforms and to assess their relationship with LPL activity and with the levels of 
the LPL activator apoA-V.  
METHODS: ApoCIII glycoforms in four groups of patients (from “Verona Heart Study” biobank,) classified according to the total plasma 
concentration of ApoCIII and different TG levels, were analyzed by a classical (isoelectric focusing/western blotting) and by a shotgun MS 
approach. LPL activity (Fluorescent assay) and ApoA-V concentration (ELISA assay) were determined, and their correlations with lipid 
metabolism parameters were analyzed. We also validated by 2D-WB some proteins previously identified by 2-DE analysis. 
RESULTS & DISCUSSION: 
Tabel 1.  Characteristics of the subjects 
groups Number of 
samples 
ApoCIII 
levels 
Fatty acids profile 
1 7 low (7.25  1.45 mg/dL) A (poly- unsaturated > 40%) 
2 5 low (7.25  1.45 mg/dL)  B (poly- unsaturated < 40%) 
3 7 high (17.31  3.98 mg/dL) A (poly- unsaturated > 40%) 
4 7 high (17.31  3.98 mg/dL) B (poly- unsaturated < 40%) 
Note: The level of apolipoprotein C-III was determined using an automated 
turbidimetric immunoassay; are considered low values ​​<9.2 mg / dL and higher than 
≥ 12.6 mg / dL. The polyunsaturated (PUFA) profile has been defined by gas 
chromatography. 
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Figure1. ApoCIII detection after IEF and diffusion blotting. (A) GROUP 1 low ApoCIII ;(B) 
GROUP 2 low ApoCIII; (C) GROUP 3 high ApoCIII;(D) GROUP 4 high ApoCIII 
The distribution of the three ApoCIII glycoforms in the selected groups of patients are 
related to the TG levels, particularly the mono-sialylated isoform (ApoCIII-1) prevails in patients with the highest 
TG levels. 
Variable Concentration Triglycerides ApoCIII 
  
LPL (μmol/ml)* 
3,10 
(2,72 -3,53) 
r= 0,034 
p= 0,805 
r= 0,188 
p= 0,165 
r= 0,153 
p= 0,259 
Apo A-V ng/ml* 
496,90       
(369,70-667,87) 
r= -0,245 
p= 0,143 
-  - 
Variable  Range (min-max) Normality value 
Apo C-III (mg/dl) 11,81 ± 3,84 3,17 - 20,44  < 10.5 
  
LPL (μmol/ml)*  3,10 
 (2,72 -3,53) 
0,78 - 7,21  -  
Apo A-V ng/ml*  496,90  
(369,70 -667,87) 
66 - 2395,95  - r = correlation coefficient, p = p-value 
 
The mean concentration of ApoAV measured in our study group (496.90 ng / ml, CI 369.70 to 667.87), falls within the normal 
range, approaching the upper limit.  Our analysis does not show significant correlations between the LPL activity, measured as 
Vmax, and plasma levels of these apolipoproteins.   
 Table2. ApoAV and LPL correlations with apolipoproteinCIII and triglycerides Table 3.Mean values, with standard deviation, range and normal values, 
relative to the concentration of apolipoprotein and LPL activity 
CONCLUSION: These data could provide important insights regarding the interaction among apoCIII glycoforms, ApoA-V level and LPL activity 
in predicting cardiovascular risk in predisposed individuals 
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Good agreement between IEF analysis and MS approach in terms of abundance % of isoforms. The MS analysis on a new set 
(n=60) of CAD patients is actually ongoing!  
 
Figure2.Chromatogram and TOF MS with the ions of the glycoforms Figure3. APOC3 glycoforms and elution profile of the APOC3_0 isoform 
